The stock price’s performance over the year has been unpredictable, resulting in a mix of pessimistic and optimistic outlooks among investors. Year to date metric has recorded a loss of -2.20%.However, over the last six months, we can see a stronger performance of -11.88%. Over the last 30 days, the price of CTSO has leaped by -8.25%. And in the last five days, it has fallen by -20.54%.
Cytosorbents Corp’s market performance has been stable in recent times. The company’s stock hit a 1-year high of $1.61 on 02/14/25 and a low of $0.70 for the same time frame on 07/01/24.
52-week price history of CTSO Stock
Analyzing a stock’s 52-week high and low prices can offer important information about its present condition and future outlook. Cytosorbents Corp’s current trading price is -44.72% away from its 52-week high, while its distance from the 52-week low is 27.14%. The stock’s price range during this period has varied between$0.70 and $1.61. The Cytosorbents Corp’s shares, which operate in the Healthcare, saw a trading volume of around 23994.0 for the day, a figure considerably lower than their average daily volume of 0.13 million over last three months.
Market Capitalization vs. Financial Performance: A Comparative Study
Cytosorbents Corp (CTSO) has experienced a quarterly decline of -9.95% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 55.72M and boasts a workforce of 149 employees.
Combining Moving Average and Trading Volume Data for Better Market Insight
Based on Barchart.com data, the company’s moving average over the 100-day period was 1.0196, with a change in price of +0.0491. Similarly, Cytosorbents Corp recorded 205,962 in trading volume during the last 100 days, posting a change of +5.58%.
CTSO’s Debt-to-Equity Ratio Cause for Concern? An In-Depth Look
The debt-to-equity (D/E) ratio is a significant metric that provides insights into a company’s financial state and market presence. By dividing a company’s current liabilities by its shareholders’ equity, the D/E ratio depicts the extent of debt used by a company to fund its assets relative to the value of its shareholders’ equity. At the time of writing, the total D/E ratio for CTSO stands at 2.42. Similarly, the long-term debt-to-equity ratio is also 2.38.
CTSO Stock Stochastic Average
As of today, Cytosorbents Corp’s raw stochastic average for the last 50 days stands at 20.45%. This is a rise compared to the raw stochastic average of the previous 20 days, which was noted at 20.45%. Furthermore, the company’s Stochastic %K and %D values for the past 20 days were 19.22% and 24.82%, respectively.
